OCULIS HOLDING AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.8 USD | 0.00% |
|
-0.42% | +5.08% |
| Jun. 11 | BofA Securities Adjusts Oculis Holding AG to $20 From $21, Maintains Buy Rating | MT |
| Jun. 11 | Baird Adjusts Price Target on Oculis Holding to $37 From $35, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Calendar
2024-08-13
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.52
CHF
Average target price
25.97
CHF
Spread / Average Target
+146.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.08% | 493M | |
| +40.80% | 53.67B | |
| +35.79% | 38.86B | |
| -8.05% | 38.76B | |
| -8.98% | 27.27B | |
| +10.69% | 25.91B | |
| -16.21% | 20.29B | |
| +31.00% | 12.78B | |
| +28.51% | 12.18B | |
| -1.67% | 11.96B |
- Stock Market
- Equities
- OCS Stock
- News Oculis Holding AG
- Oculis Holding Says its OCS-01 Diabetic Macular Edema Drug Candidate Met Efficacy Primary Endpoint in Late-Stage Study
